https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2011-01-05 15:08:172016-11-24 15:09:45SuperGen Announces Enrollment of First Patient in First in Human Trial of SGI-110 in MDS and AML Patients
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2010-12-03 16:11:112016-11-24 16:12:51SuperGen Announces Presentation of SGI-110 Preclinical Data at American Society of Hematology
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2010-12-01 16:13:332016-11-24 16:15:28Encouraging Data on Astex’s Anti-Cancer Drug AT9283 to be Presented at ASH
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2010-11-11 16:17:112016-11-24 16:19:29Encouraging Data from Phase I Studies of Astex’s Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2010-11-10 16:19:352016-11-28 12:17:50SuperGen Discontinues Clinical Development of SGI-1776
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2010-11-04 12:19:062016-11-28 12:20:18Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2010-10-12 12:21:572016-11-28 12:22:27Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok